SCHEMBL3304046

SCHEMBL3304046

COC1(OC)CCN(C(C)=O)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
USP2 O75604 2/20 0.41
ALDH1A1 P00352 3/20 0.40
CYP2C19 P33261 3/20 0.40
EPHX2 P34913 2/20 0.40
MAPK1 P28482 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2D6 P10635 4/20 0.39
TSHR P16473 2/20 0.39
CYP2C9 P11712 4/20 0.39
CYP3A4 P08684 3/20 0.38
HPGD P15428 1/20 0.37
ALOX12 P18054 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PIK3CD O00329 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28170910 0.82 CYP3A4 (0.34) CYP1A2USP2ALDH1A1CYP2C19MAPK1
SCHEMBL12045659 0.80 CYP1A2 (0.43) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL3434463 0.76 EPHX2 (0.55) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL26783934 0.75 USP2 (0.60) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL23344999 0.75 CYP1A2 (0.39) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL25628754 0.75 CYP1A2 (0.39) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL12029857 0.75 PIK3CD (0.40) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL18711878 0.74 KDM4E (0.39) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL26807125 0.74 HSD11B1 (0.39) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL15544126 0.73 USP2 (0.58) CYP1A2TDP1KDM4ESMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2935254-A1 COMPOUNDS OF 2,3-DIHYDRO-4H-1,3-BENZOXAZINE-4-ONE, METHOD FOR PREPARING THEM AND PHARMACEUTICAL FORM COMPRISING THEM C4T S.C. a.r.l. (IT) 2015-10-28 EP disclosed
EP-2114951-B9 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2015-09-02 EP disclosed
EP-2114951-B9 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2015-09-02 EP disclosed
WO-2014097188-A1 COMPOUNDS OF 2,3-DIHYDRO-4H-1,3-BENZOXAZINE-4-ONE, METHOD FOR PREPARING THEM AND PHARMACEUTICAL FORM COMPRISING THEM C4T S.C. A.R.L. (IT) 2014-06-26 WO disclosed
CN-101631792-B Novel phosphodiesterase inhibitors LEO PHARMA AS DK 2013-05-01 CN disclosed
US-8338431-B2 Phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2012-12-25 US disclosed
US-8338431-B2 Phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2012-12-25 US disclosed
US-8338431-B2 Phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2012-12-25 US disclosed
US-20100099688-A1 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2010-04-22 US disclosed
US-20100099688-A1 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2010-04-22 US disclosed
US-20100099688-A1 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2010-04-22 US disclosed
CN-101631792-A Novel phosphodiesterase inhibitors LEO PHARMA AS 2010-01-20 CN disclosed
EP-2114951-A2 NOVEL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2009-11-11 EP disclosed
WO-2008104175-A2 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2008-09-04 WO disclosed
WO-2008104175-A2 NOVEL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099688-A1 NOVEL PHOSPHODIESTERASE INHIBITORS PDE3A, PDE5A, PDE3B CYP1A2 185/4885TDP1 32/4885KDM4E 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.